Abstract | Immune responses to certain heat-shock proteins (HSPs) develop in almost all inflammatory diseases; however, the significance of such responses is only now becoming clear. In experimental disease models, HSPs can prevent or arrest inflammatory damage, and in initial clinical trials in patients with chronic inflammatory disease, HSP-derived peptides have been shown to promote the production of anti-inflammatory cytokines, indicating that HSPs have immunoregulatory potential. In this Review, we discuss the unique characteristics of HSPs that endow them with these immunoregulatory qualities.
The expression of heat-shock proteins (HSPs) can be markedly upregulated by all cells under conditions of stress: for example, increased temperature (fever); nutritional deficiency; exposure to pro-inflammatory mediators, such as tumour-necrosis factor (TNF) and interferon-γ (IFN-γ); oxidative stress; treatment with non-steroidal anti-inflammatory drugs; and viral infection [1] [2] [3] [4] . HSPs carry out crucial housekeeping functions and are MOLECULAR CHAPERONES that are important for the survival of prokaryotic and eukaryotic cells. HSPs are classified into about six families (including the HSP10, HSP40, HSP60, HSP70, HSP90 and HSP100 families) on the basis of their monomeric molecular weight, with each family consisting of at least one member but often more. HSP families are highly conserved throughout evolution, and some mammalian family members have highly conserved microbial homologues, which results in immunological cross-recognition between mammalian and microbial homologues (TABLE 1; BOX 1) . Other less conserved HSP families (such as the HSP90 family, the HSP100 family and the small HSP family, which includes HSP27 and α-B crystallin), which are not known to induce crossreactive immune responses, are not further discussed here and have been reviewed elsewhere 1, 5 . The first evidence of a role for HSPs as antigens in inflammatory responses was obtained in the 1980s in the rat model of heat-killed-mycobacteria-induced adjuvant arthritis (ADJUVANT-INDUCED ARTHRITIS) 6 . It was found that T cells isolated from rats with disease were responding to mycobacterial HSP60. Since then, immune reactivity to HSPs has been detected in other experimental models of inflammatory disease and in inflammatory diseases of humans. Recently, various studies have shown that HSP-reactive T cells have an immunoregulatory phenotype, indicating that HSPsand in particular, HSP60 and HSP70 -constitute a group of 'autoantigens' with the potential to trigger immunoregulatory pathways, which can suppress immune responses that occur in human inflammatory diseases, such as rheumatoid arthritis (RA), type 1 diabetes, and possibly atherosclerosis and allergy. Here, we review the evidence that HSP-mediated preventive and therapeutic immune interventions that are effective in animal models of chronic inflammatory diseases might also be applicable to the treatment of human disease. Consistent with this, initial clinical trials in patients with type 1 diabetes or RA have indicated the potential of HSPs to be a source of immunoregulatory peptides. In addition, we review the evidence that the immunoregulatory qualities of HSPs stem from their exceptional evolutionary conservation, which enables immune crossreactivity between exogenous microbial HSPs and self-HSPs. And, we propose that exposure to microbial First, because of their essential roles in cell survival, HSP sequences are highly conserved between different bacterial species. So, each time the immune system encounters bacteria, its initial response might be targeted to the strongly conserved regions of the bacterial HSP that are recognized by memory cells arising from previous infections with unrelated bacteria. Second, during infection, the invading microorganism experiences stress (for example, a rise in temperature and exposure to reactiveoxygen species produced in host defence), and it upregulates expression of its own HSPs, making them easily available targets for the host immune cells. Third, HSPspecific responses might be immunodominant because, as molecular chaperones, HSPs associate with other, often unfolded, newly synthesized antigenic microbial proteins or with microbial proteins that are denatured or partially unfolded as a result of stress. As a consequence, B cells with cell-surface B-cell receptors specific for a (partially unfolded) microbial antigen can internalize the associated microbial HSP together with the microbial antigen, process them both, and present peptides derived from the two proteins in the context of MHC class II molecules for recognition by T helper (T H ) cells.
Immune responses to mammalian HSPs
Despite the existence of several possible mechanisms for ensuring CENTRAL TOLERANCE to self, self-HSP-specific T and B cells have been found in association with chronic inflammation, as well as in healthy individuals 17 , as indicated by the presence of HSP-specific antibodies and both MHC-class-I-and class-II-restricted T-cell reactivity to HSPs. We now describe evidence for this apparent lack of tolerance to self-HSPs and propose potential explanations for this phenomenon.
Lack of HSP self-tolerance. The presence of a repertoire of self-HSP-reactive cells was first shown by immunization of rats with mammalian HSP60, either using vaccinia virus as a carrier system or by immunization of DNA encoding HSP60, which induced self-HSP-specific antibodies and T cells 18, 19 . However, a self-HSP-reactive immune repertoire was also shown to be present in the absence of immunization, possibly as a result of previous contact with homologous bacterial HSPs. Human cord blood was also shown to contain high frequencies of HSP60-specific T cells 20 . So, Cohen 17 proposed that HSPs -by artificial immunization with HSPs, by contact with commensal microflora or during bacterial infection -leads to the activation of self-HSP-reactive T cells that exert their immunoregulatory activities towards self-HSP-expressing inflamed tissues.
Microbial HSP60 and HSP70 are immunodominant
Immune responses to both HSP60 and HSP70 from bacteria, protozoa, fungi and helminths have frequently been detected after infection with these organisms 7 . Moreover, during bacterial infections, the bacterial members of the HSP60 and HSP70 families (GroEL and DnaK, respectively) are common targets of humoral and cell-mediated immune responses in mammals 4, 8 . In fact, before identification as a member of the HSP60 family, HSP60 was known as the common antigen of Gram-negative bacteria 9, 10 . Analysis of T-cell responses in mice immunized with Mycobacterium tuberculosis showed that ∼10-20% of the M. tuberculosis-specific T cells responded to M. tuberculosis HSP60 (REF. 11 ). Similarly, analysis of antigen specificity showed that at least 5 of 48 CD4 + T-cell clones derived from patients with leprosy responded to Mycobacterium leprae HSP70 (REF. 12 ), and marked HSP70-specific immune responses have been described in humans suffering from parasitic infections, such as malaria, leishmaniasis, schistosomiasis and filariasis 13 . Antibodies specific for both HSP60 and HSP70 of Chlamydia trachomatis have been detected at high titres in the sera of patients infected with C. trachomatis 14 , and immunodominant humoral and cellular responses to fungal HSP60 and HSP70 have also been reported 15 . Taken together, these findings indicate that HSPs are important immunogenic antigens in infection.
In healthy humans not known to have been exposed to mycobacterial infections, antibodies and T cells specific for mycobacterial HSP60 have also been detected 16 . Further characterization of the epitopes that were recognized by T cells showed that T-cell responses were frequently directed against conserved sequences, most probably as a consequence of either previous exposure to unrelated bacterial HSPs from gut microflora or infection with unrelated bacteria.
The occurrence of immunodominant immune responses to HSP60 and/or HSP70 is likely to result from several factors that are related to their function. www.nature.com/reviews/immunol R E V I E W S T-cell responses to self-HSPs. Because they are intracellular proteins, under conditions of cellular stress, self-HSPs are efficiently presented by MHC class I molecules to cytotoxic T lymphocytes (CTLs). An early report showed that CTLs raised against mycobacterial HSP60 also recognized macrophages that were subjected to various forms of cellular stress, in the absence of exogenously added antigen 25 , indicating that endogenous self-HSP60 is presented in the context of MHC class I molecules to the CTLs. In a later study, CTL-mediated lysis of macrophages that were 'stressed' by treatment with IFN-γ was inhibited when HSP60 expression was suppressed by HSP60-directed antisense oligonucleotides 26 , thereby confirming the specificity of the CTLs for HSP60. Furthermore, in patients with cancer, tumour-infiltrating lymphocyte populations were found to contain CTLs specific for self-HSP70-derived peptides 27 . In addition to their efficient presentation by MHC class I molecules, HSP-derived peptides can also be presented by MHC class II molecules. Indeed, HSP70-derived peptides are relatively prominent in peptide cohorts eluted from MHC class II molecules 28, 29 . We also obtained in vitro evidence that stressed antigenpresenting cells (APCs) were recognized by CD4 + T cells that were raised against a highly conserved mycobacterial HSP60 sequence 30 . The resultant CD4 + T-cell line responded to rat HSP60, as well as to rat splenocytes that had been heat shocked in vitro. After several rounds of re-stimulation with the conserved peptide, this T-cell line also responded in the presence of non-stressed syngeneic APCs
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. Interestingly, transfer of these T cells to model animals was shown to protect against adjuvant-induced arthritis, and they were found to produce IFN-γ, interleukin-4 (IL-4) and IL-10. So, recognition of HSPs expressed by stressed cells might induce a disease-suppressive regulatory phenotype in responding T cells. In a similar study, T cells recognizing another conserved and protective epitope in the carboxyl terminus of mycobacterial HSP60 also responded to heat-stressed APCs in the absence of exogenous antigen 32 . Together, these findings indicate the existence of CD4 + T cells with the capacity to recognize self-HSP epitopes, and they imply that, under certain conditions, such T cells might regulate disease.
HSPs are immunological targets in disease
The first findings that immune responses to HSPs have a regulatory role in inflammatory diseases were shown for mycobacteria-induced adjuvant arthritis 6 . In this model, pre-immunization with mycobacterial HSP60 administered in incomplete Freund's adjuvant (IFA) inhibited disease. After these initial findings, protective effects of microbial HSPs were seen in many other experimental disease models (TABLE 2) , and importantly, it was found that the protective effect of HSPs seemed to be independent of the antigenic relationship of the HSP with the disease-inducing antigen. So, it is possible that immune responses to HSPs could be involved in the control of human chronic inflammatory diseases that have distinct, although as-yet-unknown, initiating autoantigens. HSP60 belongs to a set of conserved self-antigens to which we are not efficiently tolerant. Therefore, it seems that HSP-reactive cells escape central tolerance and enter the periphery, where mechanisms of peripheral tolerance operate to safely contain such HSP-reactive cells. Inefficient central tolerance could result if HSPs were constitutively expressed only at low levels or had a restricted tissue-expression pattern or subcellular localization (for example, in mitochondria). However, none of these is probable, as HSPs are expressed by almost every cell type in the body and are present at high levels in the normal thymus 21, 22 . Moreover, the transgenic overexpression of mouse HSP60 in the thymus did not eliminate T-cell responses to self-HSP60 following HSP immunization 22 . So, in contrast to many other examples in which low to undetectable levels of thymic transgene expression are sufficient to drive tolerance 23 , high levels of HSP60 expression in the thymus do not lead to the deletion of HSP60-specific T cells. Therefore, it is more probable that T cells with specificity for HSPs, and possibly other stress-associated antigens, receive other as-yet-undefined survival signals during negative selection in the thymus 24 .
Regardless of the mechanisms of their selection, lack of central tolerance needs to be compensated by peripheral tolerance. Moreover, as we discuss later, HSPs are a driving factor in the generation of regulatory responses. 
HSP70
HSP70 homologues form a large family of highly related proteins with chaperone activity and are present in all groups of organisms 135 . Bacterial HSP70 (also known as DnaK) is generally present in one form. Eukaryotes have several homologues (TABLE 1) , and these are organelle (nucleus, cytosol, endoplasmic reticulum, mitochondrion or chloroplast) specific. HSP70 homologues bind transiently to unfolded polypeptide structures, and this can be reversed by ATP.
HSP70 is one of the most conserved HSPs
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. A study comparing the sequences of 2 members of the HSP70 family of Saccharomyces cerevisiae with a set of 29 HSP70 molecules from 24 other eukaryotic and prokaryotic species clearly shows the high level of conservation of HSP70 molecules: proteins from the most distantly related species have at least 45% sequence identity 137 
.
Arthritis. Following the findings of protective effects of mycobacterial HSP60 in adjuvant-induced arthritis in rats, several research groups studied immune reactivity to HSPs in human arthritis. At first, it was found that arthritic synovial-tissue samples from animals with experimentally induced arthritis and patients with RA or JUVENILE IDIOPATHIC ARTHRITIS (JIA) expressed increased levels of HSP60 (REFS 33, 34) . JIA differs from adult RA in its clinical course; if untreated, RA always develops into a non-remitting, crippling disease, whereas most patients with JIA have a restricted and, sometimes, spontaneously remitting disease. In an initial study, T cells from the synovial fluid and blood of patients HSP60 and HSP70 have been studied and identified as immune targets in RA, type 1 diabetes, systemic lupus erythematosus, atherosclerosis, DERMATOMYOSITIS, inflammatory muscle disorders, organ transplantation and cardiac surgery. Although data on human diseases are still scattered and incomplete, a picture is emerging in which expression of HSPs or immune reactivity to HSPs seems to be associated with downregulation of inflammation, rather than with induction or propagation of inflammation. Here, we focus on the three inflammatory conditions -arthritis, type 1 diabetes and atherosclerosis -for which immune responses to HSPs have been most extensively studied.
DERMATOMYOSITIS
One of a group of acquired muscle diseases that are known as inflammatory myopathies.
JUVENILE IDIOPATHIC ARTHRITIS (JIA). The most common rheumatic disease of childhood. It is characterized by local inflammation in the joints, which leads to joint destruction. www.nature.com/reviews/immunol R E V I E W S TNF-receptor-related protein), CTLA4 (cytotoxic T-lymphocyte antigen 4) and CD30 -and high levels of expression of the transcription factor FOXP3. Moreover, these CD4 + CD25 + T cells were capable of suppressing in vitro immune responses. So, HSP-activated T cells show regulatory phenotypes that are consistent with them being T Reg cells.
Studies using peptide epitopes instead of whole proteins and new techniques for the detection of antigenspecific T cells in a polyclonal population are needed to determine the molecular basis of the development of regulatory T cells and how this can be manipulated both in vitro and in vivo.
Type 1 diabetes.
In the non-obese diabetic (NOD) mouse model of type 1 diabetes, immunization with mycobacterial HSP60 has been shown to protect against disease (TABLE 2) . However, this protection depends on the form of HSP administration, because mycobacterial HSP60 causes disease earlier when administered in IFA but protects against disease when administered in phosphate-buffered saline 47 . Other studies have led to the identification of a mouse HSP60-derived peptide, known as p277 (REF. 48 ), which is effective at protecting NOD mice against insulitis. Although the protective effect of this peptide was confirmed in another rodent model of type 1 diabetes 49 , a separate study did not replicate these results 50 . Quintana et al. 51 showed that it is possible to predict resistance to future insulitis in NOD mice that have spontaneously developed natural IgG specific for epitopes within HSP60: that is, NOD mice that have 'vaccinated' themselves against HSP60 were protected from developing disease. A recent study has documented that gp96 (a member of the HSP90 family) has disease-suppressive immunomodulatory activity in NOD mice 52 , although the mechanisms involved remain to be elucidated.
Similar to the findings for animal models, the presence of autoantibodies and T cells specific for HSP60, HSP70 and HSP90 has been documented following several studies of patients with type 1 diabetes [53] [54] [55] [56] [57] [58] . For example, Cohen and colleagues 59, 60 showed that the HSP60-derived peptide p277 could bind human MHC class II molecules and induce proliferative T-cell responses in patients with type 1 diabetes. However, further studies are required to reveal the role of these responses in the disease.
Atherosclerosis. Animal models of atherosclerosis have shown a role for HSP60 in development of disease and, to a lesser extent, in protection against disease. For rabbits and mice, immunization with mycobacterial HSP60 increased disease in the presence of atherosclerosis-promoting genetic and dietary conditions 61 . However, more recent studies have shown that mycobacterial HSP60, when administered orally or intranasally, has the potential to suppress induced atherosclerosis 62, 63 (TABLE 2) . So, it seems that, although immune responses to HSP60 are associated with development of disease, these responses can be manipulated to induce disease-suppressive regulation.
with JIA or RA proliferated in response to mycobacterial HSP60 (REFS 35, 36) . However, in contrast to patients with RA or healthy control individuals, cells from patients with JIA had substantial proliferative responses to self-HSP60. Other research groups also showed responses to both human HSP60 and other HSPs, including Escherichia coli DnaJ (also known as HSP40), in patients with JIA 37,38 , indicating that the inflammation in JIA induced immune responses to a variety of HSPs. Further studies showed that CD4 + T-cell responses to human HSP60 at the onset of JIA correlated with responses to mycobacterial HSP60 and with a favourable prognosis 39 . So, these findings indicated that microbial-HSP-crossreactive responses of T cells to endogenous human HSP60 might have a regulatory role in the course of self-remitting JIA. Consistent with this, T cells recognizing self-HSP60 that are isolated from patients with JIA mainly have a regulatory phenotype: after activation with human HSP60, T cells from patients with remitting JIA express CD25 and CD30 and can produce regulatory cytokines, such as IL-4, IL-10 and transforming growth factor-β (TGF-β) 40 . Studies of adult RA have shown a more diverse situation with regard to T-cell proliferation in response to HSPs and have shown a role for different HSPs, including the HSP70-family member BIP [41] [42] [43] . However, similar to the findings for patients with JIA, human HSP60 seems to be driving the production of regulatory cytokines in patients with RA. When stimulated with human HSP60, HSP60-reactive synovial-fluid T cells from patients with RA produced less IFN-γ and more IL-4 than when stimulated with bacterial HSP60. Importantly, these HSP60-specific T-cell lines suppressed TNF production by autologous peripheralblood mononuclear cells (PBMCs) in co-cultures 44 . Moreover, it seems that disease severity of RA might depend, in part, on the capacity of human HSP60 to induce the production of IL-10 by mononuclear cells 44, 45 . During periods of active arthritis, inflammation in the joint leads to local cellular stress and therefore the upregulation of self-HSP expression in the synovial tissue 33,34 . We propose that T cells recognizing these selfHSPs can be activated in the inflamed joint, thereby inducing the activation of several regulatory T-cell subsets, including the following: T H 2 cells, which produce IL-4 and express GATA-binding protein 3 (GATA3); T H 3 cells, which produce TGF-β; T regulatory 1 (T R 1) cells, which produce IL-10; and CD4 + T cells showed high levels of CD25 expression, combined with cell-surface expression of T Reg -cell markers -such as GITR (glucocorticoid-induced (TLRs), or to their stress inducibility or their molecular conservation, which results in immune crossreactivity between bacterial and mammalian homologues (FIG. 1) . Do HSPs induce regulation through the innate immune system? Mammalian and bacterial HSPs have been described to directly activate APCs 71 , including macrophages and dendritic cells (DCs), probably through binding to cell-surface receptors such as CD14, CD40, TLRs and the scavenger receptors CD36, CD91 and LOX1 (lectin-type oxidized LDL receptor 1) 72, 73 . Such immune activation might contribute to the breaking of tolerance to autoantigens, such as HSP70, leading to the induction of autoimmune disease 74 . The observation that mammalian HSPs interact with TLRs is intriguing, as it refutes the idea that TLRs interact exclusively with microbial antigens. So, it is tempting to assume that an individual TLR can interact with important APC-activating molecules, whether they are foreign (such as lipopolysaccharide (LPS) or, potentially, bacterial HSP) or host derived (such as mammalian HSP). However, controversy has arisen, because it was argued that many of the reported pro-inflammatory effects that result from exposure of cells to microbial or recombinant HSP are mediated through contaminating LPS or other microbial compounds 75, 76 . Although this might be true, some aspects of TLR triggering by HSPs seem to differ from TLR triggering by other microbial compounds. For example, the initiation of signalling through TLRs by HSP60 was found to require endocytosis, whereas LPS can signal from the cell surface 77 . Therefore, further experiments are required to resolve this issue, particularly studies of the putative HSP receptors that are known to bind LPS, such as TLR2, TLR4 and CD14. If it is shown that the induction of pro-inflammatory-cytokine production by HSPs is mediated by contaminants and not by the HSPs themselves, then it will be necessary to determine whether HSPs have other effects on the innate immune system.
Recent studies allude to other such effects. In the absence of cell-surface TLR4, Habich et al. 78 showed binding of human HSP60 to a specific and saturable receptor at the cell surface of macrophages. The putative receptor differed from the receptor for HSP70, HSP90 or HSP96. However, on triggering of this receptor, no cytokines were produced. In another study, MacAry et al. 79 showed that mycobacterial HSP70 triggered calcium-mediated signalling in DCs. This signalling was not observed after treatment with LPS, and calciummediated signalling is not a feature of signalling through TLRs. So, this effect is unlikely to be mediated by LPS and TLR4. Also, Zanin-Zhorov et al. 80 have shown that mammalian HSP60 has a direct innate effect on T cells, which is mediated through TLR2 and is independent of LPS; this results in activation of T-cell adhesion and inhibition of chemokine-receptor expression. In this respect, HSP60 has recently been shown to modulate the expression of transcription factors involved in T H 1-versus T H 2-cell differentiation: HSP60 downregulates expression of the T H 1-cell-promoting transcription factor T-bet, as well as nuclear factor-κB and the Atherosclerosis is thought to develop as a result of an inflammatory response to an initial injury of an arterial wall, with macrophages and T cells being important in atherosclerotic plaques at all stages of development, mainly through their production of pro-inflammatory mediators 61 . Infection has been proposed as a possible trigger for the initial arterial-wall injury and is thought to (together with other factors) lead to further damage based on an autoimmune process 61 . In humans, several microorganisms have been implicated as triggering factors for atherosclerosis, most importantly Chlamydophila pneumoniae and cytomegalovirus (CMV) 64, 65 , and only a few candidate autoantigens have been described. As well as oxidized low-density lipoprotein (LDL), HSP60 might be an important autoantigen in atherosclerosis. High levels of autoantibodies specific for human HSP60 have been reported to be associated with cardiovascular disease and coronary heart disease 61 . However, some studies of coronary heart disease have shown the presence of increased levels of IgG specific for C. pneumoniae HSP60 but not human HSP60 (REF. 66 ). This lack of human HSP60-specific antibodies is inconsistent with previous suggestions that crossreactive responses to self-HSP60 might contribute to disease progression. Recently, a B-cell epitope of HSP60 was identified that has homology with two human CMV-encoded proteins 64 . Patients with coronary heart disease were found to have antibodies specific for this human HSP60 epitope, as well for the homologous viral peptides, whereas healthy control individuals did not. So, infection with CMV might induce a cascade of immune responses that lead to damage of the endothelium through molecular mimicry involving HSP60 (REF. 64 ). A role for a similar mechanism of molecular mimicry between C. pneumoniae HSP60 and human HSP60 has previously been proposed in the pathogenesis of the endothelial inflammation and damage that occurs in coronary heart disease 66, 67 . However, although this hypothesis has received much attention, further studies are required to clarify the contribution of self-HSP-directed immunity to atherosclerosis.
By contrast, the presence of high levels of HSP70 in human sera seems to be associated with protection against cardiovascular disease 68, 69 . So, although there is some (albeit inconclusive) evidence that HSP60 might be involved in the development of disease (possibly through a molecular mimicry mechanism), in certain circumstances, such as after oral administration of HSP60 to animals or when serum levels of HSP70 are high, HSPs might have disease-suppressive capacities.
Mechanisms of regulation by HSP60 and HSP70
The analysis of immune responses to HSPs in experimental models and in patients has indicated the capacity of HSPs to induce regulatory T-cell responses (as described earlier). This capacity has not been seen for non-HSP antigens, such as other relatively conserved and immunogenic bacterial antigens 70 . So, HSPs might have unique characteristics that endow them with this regulation-inducing capacity. Such characteristics might be related to the interactions of HSPs with receptors of the innate immune system, such as Toll-like receptors www.nature.com/reviews/immunol R E V I E W S BIP (an HSP70-family member) was found to trigger the production of anti-inflammatory cytokines by PBMCs 83 . Interestingly, Detanico et al. 84 have recently observed that synovia-derived monocytes obtained from patients with arthritis produce IL-10 in the presence of LPS-free mycobacterial HSP70. In the same study, mycobacterial HSP70 was shown to delay maturation of mouse bonemarrow-derived DCs. It is interesting, therefore, that intracellular-signalling molecule NFATp (pre-existing component of nuclear factor of activated T cells; also known as NFATc2), whereas it upregulates the expression of the T H 2-cell-promoting transcription factor GATA3. This results in decreased secretion of the proinflammatory cytokines TNF and IFN-γ and increased secretion of the regulatory cytokine IL-10 by HSP60-activated T cells 81, 82 . Also, the stress-inducible protein study, Kimura et al. 92 showed that Lewis rat T cells activated by infection with Listeria monocytogenes were specific for the conserved sequence in L. monocytogenes HSP70 that spans amino acids 234-252. This sequence has 58% identity with the homologous rat HSP70 sequence, and in a separate study, immunization with this peptide protected rats against adjuvant-induced arthritis 91 . The HSP70-specific T cells were induced at a relatively late stage of infection, when the bacteria had been cleared, and were able to suppress pro-inflammatory responses generated by the L. monocytogenes infection through the production of TGF-β and IL-10. These findings were consistent with a situation in which T cells that recognize this HSP70 epitope were involved in terminating T H 1-cell-mediated inflammation after the "battle against L. monocytogenes has been won" 92 . Similarly, the CD4 + T-cell line described earlier, which was raised against a conserved core peptide of mycobacterial HSP60 and crossreacted with endogenous rat HSP60, produced regulatory cytokines (such as IL-4, IL-10 and IFN-γ) in response to irradiated naive APCs
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. Finally, the protection mediated by mycobacterial HSP70 in PROTEOGLYCAN-INDUCED ARTHRITIS in BALB/c mice (TABLE 2) seemed to be mediated through the production of regulatory cytokines by T cells. Interestingly, not only T cells specific for HSP70 but also T cells specific for proteoglycan were found to produce IL-10 in animals that were protected by the administration of HSP70 (S. Berlo, C. ten Brink, P. J. van Kooten, R.v.d.Z., C. P. Broeren and W.v.E., unpublished observations).
Regulation by self-HSP-crossreactive T cells. Self-HSPcrossreactive T cells that escape central deletion might be activated or primed in the gut following recognition of HSPs from commensal bacteria, owing to the homology between bacterial and mammalian HSPs (FIG. 1) . However, it is well known that (in most cases) antigenic exposure at the gut mucosa leads to the induction of tolerance, not only local tolerance but also systemic tolerance, through mechanisms that include the production of regulatory T cells [93] [94] [95] . So, continuous exposure of such cells in the mucosa to commensal microflora HSPs might favour the induction of MUCOSAL TOLERANCE in this self-HSP-crossreactive repertoire. This possibility is supported by the evidence that commensal microflora might promote resistance to the induction of autoimmunity (such as arthritis 96 ) and that, in the case of microbial HSP60, oral administration of small quantities effectively inhibited ongoing adjuvant-induced arthritis in rats 97 . Furthermore, changes in the composition of intestinal microflora (for example, following the administration of antibiotics that promote the presence of E. coli) have been shown to induce resistance to adjuvant-induced arthritis 98 and to elicit T-and B-cell reactivity to HSPs after immunization with microbial HSPs 99 . In addition to contact with the tolerizing environment of the gut mucosa, the HSP-specific T-cell repertoire might also receive tolerizing signals from self-HSPs elsewhere in the body (FIG. 1) . Non-professional APCs might upregulate expression of HSPs under conditions of stress and present self-HSP epitopes to T cells in the signalling through TLR2 and TLR4 in DCs is not only associated with the production of T H 1 cytokines but also with the induction of the regulatory cytokine IL-10 (REFS 85,86). In addition, heat shock is known to increase LPS-induced production of IL-10 and to suppress LPSinduced production of the pro-inflammatory cytokine IL-12 (REF. 87 ). This latter finding is consistent with the suggestion that IL-10 is a stress cytokine 88 . Taken together, the accumulating evidence indicates that innate immune responses to HSP60 and HSP70 might 'set the scene' for a regulatory response by the adaptive arm of the immune system (FIG. 1) .
Microbial HSPs trigger self-HSP-crossreactive regulatory T cells. We have previously shown that immunization of Lewis rats with mycobacterial HSP60 elicited protection against adjuvant-induced arthritis 6 and that this protection could be transferred to naive animals by transfer of T cells specific for a conserved mycobacterial HSP60 sequence 30 (as discussed earlier). These T cells were shown to crossreact with homologous peptides derived from rat HSP60, as well as with heat-shocked autologous splenocytes. Immunization with this conserved peptide protected rats against adjuvant-induced arthritis, as well as arthritis induced by avridine (another adjuvant). In fact, of all the epitopes that have been analysed (from both mycobacterial HSP60 and HSP70), only those epitopes that induced self-HSP-crossreactive T cells could protect against disease 30,89-91 (FIG. 2) . Therefore, the induction of regulatory self-HSP-crossreactive T-cell responses seems to be an attractive explanation for the protection seen in these models. In all cases, cells exposed to pro-inflammatory mediators will upregulate the expression of endogenous HSPs, which might therefore become targets for recognition by crossreactive T cells. In this way, their regulatory effects might remain localized to the site of inflammation.
In several studies, T cells crossreacting with selfHSPs were found to produce regulatory cytokines, notably IL-10 (REFS 51,89,91). For example, in an elegant www.nature.com/reviews/immunol R E V I E W S expression is likely to be a contributory factor to effective HSP-directed immunoregulation (FIG. 3) .
Clinical trials in autoimmune diseases
Most conventional therapies for inflammatory diseases in humans are based on non-specific immunosuppression, such as that mediated by steroids or cytotoxic agents. More recent strategies include the blockade of several pro-inflammatory-cytokine pathways, such as those that involve TNF and IL-1. However, none of these strategies reverses the pro-inflammatory process or cures the disease. When treatment is stopped, a reactivation of inflammation occurs within months, thereby prompting life-long treatment with immunosuppressive agents. This inevitably leads to serious side-effects 107 ; therefore, there is a need for novel treatments for human autoimmune disease. For patients with type 1 diabetes, a small-scale, early-phase clinical trial showed that treatment with a non-activating monoclonal antibody specific for CD3 can lead to sustained or improved production of insulin for up to 12 months after treatment, possibly through the induction of regulatory T cells instead of through direct suppression of T cells 108, 109 . Ideally, therapy for autoimmune and other inflammatory diseases should be specific and aimed at modulating immune responses that are involved in inflammation. In experimental models of autoimmunity, antigen-specific therapy (for example, therapy that induces mucosal tolerance) has proven successful 110 . However, a lack of knowledge about suitable targets (autoantigens) has so far frustrated the translation of these studies from animal models to humans. HSPs seem to be ideal antigens for immunotherapy, because expression of HSPs is upregulated at the site of inflammation; therefore, immunotherapy directed against HSPs would be site specific. Moreover, findings from animal models and from ex vivo and in vitro studies of cells isolated from patients with inflammatory diseases strongly indicate that HSPs have a natural role in the control of inflammation. So, targeting HSPs could provide a boost for normal counter-regulatory immune responses. Some immunotherapies involving HSPs are already available, and examples of these are listed in TABLE 3. OM-89 is a glycoprotein-rich, endotoxin-free extract of E. coli that was developed in the 1980s as a possible treatment for RA. Results from several multicentre placebo-controlled trials showed that OM-89 ameliorated arthritis symptoms to a similar extent or better than conventional antirheumatic drugs, such as gold and penicillamine, and it had considerably fewer side-effects 111, 112 . Similar to other antirheumatic drugs, the mechanism of OM-89 activity is unclear. However, Polla et al. 113 showed the presence of high levels of E. coli HSP60 in OM-89, and animal studies have shown that treatment with OM-89 leads to HSP60-and HSP70-specific immunity, indicating that this immunity might be crucial for its clinical efficacy 114, 115 . Unfortunately, there are no available data about the effects of OM-89 on the immune response to HSPs in individuals with RA.
absence of co-stimulation, driving such T cells into a state of anergy 100 . Such anergic T cells might in fact have regulatory functions, either through the production of IL-10 (REF. 101) or through the induction of immunomodulatory APCs 102 . Moreover, the similar sequences of self-and microbial HSPs might endow self-HSP epitopes with ALTERED-PEPTIDE-LIGAND-like qualities, thereby triggering regulation by HSP-crossreactive T cells. In support of this, we have shown that T cells specific for the conserved mycobacterial HSP60 epitope that spans amino acids 256-265 were modulated by stimulation with the closely related but 'altered' homologous sequence from the rat 103 . These modulated T cells showed downregulation of expression of the T-cell receptor (TCR), upregulation of expression of some co-stimulatory molecules, production of IL-4 and absence of proliferation 103 . A similar partial agonistic T-cell-response pattern was seen when these cells were stimulated with stressed APCs 103 . Finally, if self-HSP epitopes impose a regulatory mode on HSP-reactive T cells and function as targets of regulatory responses, one can propose that relative expression levels of self-HSP epitopes are crucial for their efficacy in exerting these functions. Indirect evidence in favour of this possibility stems from findings that arthritis-prone Lewis rats were more resistant to upregulation of HSP60 expression by PBMCs, splenocytes and cells from the ankle-joint synovium than were arthritis-resistant Fischer rats 104 . So, there is genetic variation in HSP expression levels. Similarly, in a study of children with the autoimmune disease idiopathic thrombocytopaenic purpura, only 1 of 29 patients showed detectable levels of HSP60 expression by lymphocytes, although this HSP was detected in all 30 control individuals 105 . Although the evidence is indirect, these observations might indicate that stress-inducible selfHSPs have a crucial role in disease-protective immunoregulation. One could speculate that reduced capacity to upregulate HSPs as an individual ages 106 might contribute to decreasing resistance to chronic diseases in elderly individuals. By contrast, an increased level of HSP ALTERED-PEPTIDE LIGAND A peptide that has high homology with the sequence of an agonist peptide and induces only a partial response by T cells specific for the agonist peptide. capacity of the pancreas) and insulin dependency compared with treatment with a placebo. Moreover, the treatment had an immunomodulatory effect on the in vitro T-cell response to both the peptide and human HSP60, favouring a more T H 2-like response by the T cells of individuals who received the peptide 121, 122 . Regardless of the clinical outcome of the follow-up studies on both dnaJP1 and p277, these initial trials show great promise because the peptides target and modulate HSP-specific T cells in ongoing autoimmune diseases. An important step towards immunotherapy with HSP60 has been made by the recent discovery of HSP60 T-cell epitopes that bind multiple HLA-DR molecules. Using a computer algorithm developed by Sette 123 , eight MHC-class-II-restricted T-cell epitopes that are specifically recognized in most patients with JIA were identified. Interestingly, one of the novel epitopes was strikingly similar to the peptide that was protective against experimentally induced arthritis, so it could be a good candidate for HSP60-based immunotherapy for patients with arthritis 124 .
Concluding remarks
Immune responses to HSP60 and HSP70 have been documented for most chronic inflammatory diseases and experimental models of inflammatory diseases. Findings in studies of patients with JIA, in which responses to human HSP60 correlated with disease remission, and in experimental models, in which induced responses suppressed disease, have indicated that responses to HSPs are associated with the regulation of anti-inflammatory responses. These findings also might indicate that chronic inflammatory diseases have underlying deficiencies in such regulatory responses. So, we anticipate that immune manipulation directed at the induction of such anti-inflammatory regulation will lead to novel immunoregulatory interventions. At present, with the resurgence of interest in regulatory T cells, HSP60 and HSP70 seem to be attractive targets for such interventions. The evidence from animal models and clinical trials is consistent with this supposition. However, successful clinical development is expected to depend, at least partly, on the elucidation of several gaps in our understanding of the nature of the regulatory mechanisms of HSPs.
One unresolved issue is the mechanism by which self-HSP-reactive T cells escape central tolerance. This might be intrinsic to the proteins themselves, but alternatively and more attractively, it might be Evidence that HSPs might be targets of regulation comes from studies of autologous haematopoietic stem-cell transplantation (HSCT). Autologous HSCT is a treatment for severe, therapy-resistant autoimmune diseases, and it is remarkably efficacious for the treatment of JIA 116 . The mechanism of autologous-HSCTinduced disease remission is unknown, and it does not seem to depend on induced immunosuppression or on the presence or absence of potential autoreactive T cells in the autologous graft. De Kleer and colleagues (I. M. De Kleer, B. Vastert, M. R. Klein, G. Teklenburg, G.Arkesteijn, G. P. Jung, S.Albani,W. Kuis, N. M.Wulfraat and B.P., unpublished observations) suggest a possible explanation for the therapeutic effects of autologous HSCT on JIA. They showed that, after autologous HSCT, the repopulating immune system favours the clonal expansion of CD4 + CD25 + T cells expressing FOXP3, which might facilitate a tolerogenic microenvironment. They used a T-cell capture assay 117 to sort and characterize a pure population of antigen (self-HSP60)-specific T cells. Before autologous HSCT, such antigenspecific T cells preferentially express T-bet and IFN-γ, whereas after autologous HSCT the same population of cells express high levels of GATA3 and IL-10. This change in phenotype of the HSP60-specific T cells indicates that tolerization of these cells might allow them to cooperate with other tolerogenic cells to achieve the sustained tolerance that is seen after autologous HSCT.
Recently, the results of a Phase I/II trial of direct immunomodulation with an HSP peptide were published 118 . The peptide, known as dnaJP1, is derived from a bacterial HSP40 (a co-chaperone for HSP70), which naturally also contains the 'shared epitope', an HLA-derived sequence associated with RA 119 . Because this peptide induced in vitro pro-inflammatory responses by T cells from untreated patients who have active, early RA 120 , it was thought that dnaJP1 was conceptually different from HSP60 -an example of self-non-self crossreactivity that is disease promoting. By contrast, after oral administration of dnaJP1 to patients with RA, no toxic effects were observed, and a change from pro-inflammatory to tolerogenic T-cell responses to dnaJP1 occurred 118 .
Other promising results were obtained from trials in patients with type 1 diabetes. Treatment with three subcutaneous injections of mammalian HSP60-derived peptide p277 formulated in vegetable oil (known as Diapep277) had remarkable beneficial effects on both C-peptide concentrations (a marker of insulin-producing One attractive aspect of immune intervention using HSPs is that the pathways used might be physiological. Given that our immune system is continuously exposed to these proteins (from the gut microflora, during bacterial infection and following administration of antibacterial vaccines that contain bacteria), these exposures must have led to the cross-recognition of self-HSPs and to the ensuing regulation in most normal individuals. In fact, such exposures might contribute to a well-balanced immune system, and disruption of this balance (perhaps through reduced exposure to HSPs) might be a contributory factor to the increased occurrence of allergy and autoimmune disease that is seen in Westernized countries.
Recognition of HSPs might be an intrinsic element of all immune responses, and it might be important in dampening down immune responses. If so, the manipulation of HSP-targeted immunoregulation might offer appealing opportunities for novel therapies for chronic inflammatory diseases or for preventive vaccination against conditions such as atherosclerosis 132 . associated with their stress-dependent upregulation by thymic APCs, which might occur together with the expression of signalling molecules that promote cell survival. Some evidence that HSP60-reactive T cells have a survival advantage has been shown for CD4 + CD28
null T cells in the periphery. It was observed that senescent CD4 + CD28
null T cells, which might have a survival advantage through ligation of NKG2D (natural killer group 2, member D) by its stress-inducible ligands MICA (MHC-class-I-polypeptide-related sequence A) and MICB, are relatively resistant to apoptosis and can have regulatory functions and specificity for self-HSP60 .
Another crucial issue that remains to be resolved is whether positive selection in the thymus leads to the production of naturally occurring HSP-reactive T Reg cells. Although the presence of FOXP3-expressing HSP-specific T cells after autogolous HSCT of children clearly indicates that this is possible, further studies are needed to clarify this issue. www.nature.com/reviews/immunol
